ahlam1399
09-25-2015, 01:03 AM
U.S. appeals court upholds Shire?s patents on hyperactivity drug
(Reuters) - A U.S. appeals court has upheld drugmaker Shire's patents for its top-selling drug Vyvanse, blocking five generic drug makers from launching cheaper versions of the drug to treat attention deficit hyperactivity before 2023.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654199/s/4a240789/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/businessNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/businessNews?a=VsWApYIw5Q4:SPfJl3akug8:yIl2AUoC8zA ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=VsWApYIw5Q4:SPfJl3akug8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/businessNews?a=VsWApYIw5Q4:SPfJl3akug8:F7zBnMyn0Lo ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=VsWApYIw5Q4:SPfJl3akug8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/businessNews?a=VsWApYIw5Q4:SPfJl3akug8:V_sGLiPBpWU )
http://feeds.feedburner.com/~r/reuters/businessNews/~4/VsWApYIw5Q4
(Reuters) - A U.S. appeals court has upheld drugmaker Shire's patents for its top-selling drug Vyvanse, blocking five generic drug makers from launching cheaper versions of the drug to treat attention deficit hyperactivity before 2023.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654199/s/4a240789/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/businessNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/businessNews?a=VsWApYIw5Q4:SPfJl3akug8:yIl2AUoC8zA ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=VsWApYIw5Q4:SPfJl3akug8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/businessNews?a=VsWApYIw5Q4:SPfJl3akug8:F7zBnMyn0Lo ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=VsWApYIw5Q4:SPfJl3akug8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/businessNews?a=VsWApYIw5Q4:SPfJl3akug8:V_sGLiPBpWU )
http://feeds.feedburner.com/~r/reuters/businessNews/~4/VsWApYIw5Q4